Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Iterum Therapeutics is a biotechnology business based in the US. Iterum Therapeutics stocks (ITRM.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.252 – an increase of 0.8% over the previous week. Iterum Therapeutics employs 13 staff and has a market cap (total outstanding stock value) of $45.8 million.
Finder's Pick for
Beginners
Finder's Pick for
Free Trades
Finder's Pick for
Commodity Stocks
Finder's Pick for
Global Trading
| Latest market close | $0.25 |
|---|---|
| 52-week range | $0.19 - $2.52 |
| 50-day moving average | $0.31 |
| 200-day moving average | $0.46 |
| Wall St. target price | $1.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.56 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $0.252 from 2022-05-23
| 1 week (2022-05-17) | 0.80% |
|---|---|
| 1 month (2022-04-21) | -8.73% |
| 3 months (2022-02-22) | -28.10% |
| 6 months (2021-11-24) | -49.19% |
| 1 year (2021-05-25) | -77.50% |
|---|---|
| 2 years (2020-05-22) | -93.28% |
| 3 years (2019-05-24) | 6.26 |
| 5 years (2017-05-21) | N/A |
| Gross profit TTM | $37,000 |
|---|---|
| Return on assets TTM | -24.68% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $0.28 |
| Market capitalisation | $45.8 million |
TTM: trailing 12 months
We're not expecting Iterum Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Iterum Therapeutics's shares have ranged in value from as little as $0.185 up to $2.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iterum Therapeutics's is 1.0693. This would suggest that Iterum Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. .
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…Learn more about apps like Wealthsimple to find the best trading platform for your unique set of needs.
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
